Saxenda: what it is, cost and alternatives
Saxenda is the brand name for liraglutide — a glp-1 receptor agonist (daily) — FDA-approved for chronic weight management. Typical cost: Daily injection; pricing varies. Generic liraglutide has entered the market.. Because it shares an active ingredient with other brands and with compounded preparations, patients often compare pathways on price and access.
What is Saxenda, and who is it for?
Liraglutide is a once-daily GLP-1 receptor agonist, FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management. It predates the weekly agonists and generally produces more modest average weight loss, but daily dosing gives some patients finer control over side effects.
For the molecule-level detail — mechanism, trial evidence, side effects and warnings — see our full liraglutide guide.
What does Saxenda cost?
Daily injection; pricing varies. Generic liraglutide has entered the market.
Our GLP-1 cost guide normalizes every cash and insured pathway side by side.
What are the alternatives to Saxenda?
Depending on eligibility and budget, patients weigh other brand GLP-1 drugs, compounded preparations where lawfully available, and lifestyle-plus-clinical programs. Compare options in our best GLP-1 programs ranking and most affordable compounded tirzepatide guide.
Frequently asked questions
What is Saxenda used for?
Saxenda is FDA-approved for chronic weight management. Its active ingredient is liraglutide.
How much does Saxenda cost?
Daily injection; pricing varies. Generic liraglutide has entered the market.. See our cost comparison for cash and insurance pathways.
What is the difference between Saxenda and compounded liraglutide?
Saxenda is an FDA-approved finished drug. Compounded liraglutide is prepared by a pharmacy, is not FDA-approved, and its routine compounding is now restricted. See our compounded liraglutide guide.
Sources
- U.S. Food and Drug Administration — Saxenda prescribing information and label.
- Manufacturer pricing and savings program pages (verify current terms).
- Our normalized cost analysis, prices verified August 4, 2026.